PD L1 News and Research

RSS

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Targeting metabolic reprogramming to overcome immune suppression in head and neck cancer

Head and neck cancer remains a major global health challenge, ranking among the six most common cancers worldwide and claiming hundreds of thousands of lives each year.

5 Sep 2025

Lactylation drives tumor progression and immune evasion in triple negative breast cancer

Breast cancer maintains its position as the most prevalent malignancy in women worldwide, with triple-negative breast cancer (TNBC) representing the most treatment-resistant subtype due to limited therapeutic targets and frequent relapse.

18 Aug 2025

Plasma proteomics study unlocks predictive biomarkers for TNBC immunotherapy

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option.

17 Aug 2025

Adding MET inhibitor enhances immune response against small cell lung tumors

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research Institute, in collaboration with researchers from the CIBERONC cancer research network.

12 Aug 2025

Exosomes play a dual role in cancer progression and immune regulation

Tiny extracellular vesicles known as exosomes are emerging as key regulators of the tumor microenvironment (TME), influencing how cancer progresses, spreads, and responds to treatment.

7 Aug 2025

Targeting lactate metabolism offers new avenues for cancer treatment

Lactic acid (LA) has transitioned from being perceived as a mere glycolytic waste product to a pivotal regulator of tumor-immune crosstalk.

5 Aug 2025

New molecular insights reveal why some bladder cancers resist chemotherapy

About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy.

31 Jul 2025

T cell senescence shapes cancer prognosis and immunotherapy response

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence through multiple pathways, including persistent stimulation by tumor-associated antigens, metabolic pathway alterations, activation of chronic inflammatory responses, proliferation of immunosuppressive cells, and T cell damage caused by tumor radiotherapy and chemotherapy.

31 Jul 2025

Cancer-associated fibroblasts exhibit paradoxical effects on immunotherapy

Cancer-associated fibroblasts (CAFs) – critical but enigmatic players in tumors – exhibit "paradoxical" effects on immunotherapy, according to a new review in Clinical and Translational Discovery.

31 Jul 2025

Scarred liver tissue creates fertile ground for cancer development

Over 80% of hepatocellular carcinoma (HCC) – the third-leading cause of cancer deaths globally – emerges from advanced liver fibrosis or cirrhosis. A comprehensive review in Hepatology International synthesizes decades of research to reveal how scarred liver tissue becomes a breeding ground for cancer.

31 Jul 2025

Cancer immunotherapies linked to increased risk of liver cholestasis

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls.

30 Jul 2025

Understanding immune drift in biologic therapy for inflammatory skin diseases

Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4).

28 Jul 2025

Different anti-PD-L1 antibodies show varied results in tumor growth inhibition

Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors.

24 Jul 2025

New diagnostic test identifies head and neck cancer patients curable by surgery alone

Researchers developed a diagnostic test based on the LIMA1-alpha protein to distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone, without the need for radiation or chemotherapy.

23 Jul 2025

Radiation primes the immune system to attack lung tumors resistant to immunotherapy

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to the treatment, leading to positive outcomes for patients, according to new research by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Netherlands Cancer Institute.

22 Jul 2025